secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001213900-25-068190
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed to present INM-901 preclinical data at AAIC 2025; long-term study shows multi-modal activity
--------------------------------------------------------------------------------

- Preclinical data from INM-901 program presented at Alzheimer's Association International Conference (AAIC) 2025 in Toronto.
- Long-term study in 5xFAD mouse model with advanced disease; treatment duration longer than previous studies.
- INM-901 reduced inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL in dose-dependent manner.
- Immunohistochemistry showed dose-dependent reduction in amyloid-beta immunoreactivity and partial restoration of MAP2.
- Behavioral improvements: cognitive function, anxiety-related behavior, sensory responsiveness restored or approaching normal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025068190/0001213900-25-068190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025068190/ea0250489-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-068190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer